Verena Angerer
Rechtsmedizin · Dept. IV
Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3‐fluorophenmetrazine (3‐FPM)
Grumann C, Huppertz L, Bisel P, Angerer V, Auwärter V. Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3‐fluorophenmetrazine (3‐FPM). Drug Testing and Analysis 2019; Epub ahead of print
19.02.2019Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3‐fluorophenmetrazine (3‐FPM)
19.02.2019Drug Testing and Analysis 2019; Epub ahead of print
Grumann Christina, Huppertz Laura M., Bisel Philippe, Angerer Verena, Auwärter Volker
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)
Moosmann B, Bisel P, Westphal F, Wilde M, Kempf J, Angerer V, Auwärter V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864). Drug Test Anal 2019; 11:541-549.
05.02.2019Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)
05.02.2019Drug Test Anal 2019; 11:541-549
Moosmann Björn, Bisel Philippe, Westphal Folker, Wilde Maurice, Kempf Jürgen, Angerer Verena, Auwärter Volker
5F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA
Angerer V, Franz F, Moosmann B, Bisel P, Auwärter V. 5F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. Forensic Toxicol 2018; 37:186-196.
13.11.20185F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA
13.11.2018Forensic Toxicol 2018; 37:186-196
Angerer Verena, Franz Florian, Moosmann Björn, Bisel Philippe, Auwärter Volker
Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples
Mogler L, Franz F, Wilde M, Huppertz L, Halter S, Angerer V, Moosmann B, Auwärter V. Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples. Drug Test Anal 2018; 10:1417-1429.
23.05.2018Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples
23.05.2018Drug Test Anal 2018; 10:1417-1429
Mogler Lukas, Franz Florian, Wilde Maurice, Huppertz Laura M, Halter Sebastian, Angerer Verena, Moosmann Björn, Auwärter Volker
Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples
Mogler L, Moosmann B, Kassiou M, Banister S, Longworth M, Weinfurtner G, Angerer V, Rentsch D, Franz F, Auwärter V. Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. Drug Test Anal 2017; 10:196-205.
24.05.2017Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples
24.05.2017Drug Test Anal 2017; 10:196-205
Mogler Lukas, Moosmann Björn, Kassiou Michael, Banister Samuel D, Longworth Mitchell, Weinfurtner Georg, Angerer Verena, Rentsch Daniel, Franz Florian, Auwärter Volker